SI1567140T1 - Sinergistična kombinacija, ki obsega roflumilastin (R;R)-formoterol - Google Patents

Sinergistična kombinacija, ki obsega roflumilastin (R;R)-formoterol

Info

Publication number
SI1567140T1
SI1567140T1 SI200331345T SI200331345T SI1567140T1 SI 1567140 T1 SI1567140 T1 SI 1567140T1 SI 200331345 T SI200331345 T SI 200331345T SI 200331345 T SI200331345 T SI 200331345T SI 1567140 T1 SI1567140 T1 SI 1567140T1
Authority
SI
Slovenia
Prior art keywords
roflumilast
formoterol
synergistic combination
treatment
relates
Prior art date
Application number
SI200331345T
Other languages
English (en)
Slovenian (sl)
Inventor
Rolf Beume
Daniela Bundschuh
Degenhard Marx
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of SI1567140T1 publication Critical patent/SI1567140T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200331345T 2002-11-27 2003-11-26 Sinergistična kombinacija, ki obsega roflumilastin (R;R)-formoterol SI1567140T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02026504 2002-11-27
EP03780056A EP1567140B1 (en) 2002-11-27 2003-11-26 Synergistic combination comprising roflumilast and (r,r)-formoterol
PCT/EP2003/013266 WO2004047828A1 (en) 2002-11-27 2003-11-26 Synergistic combination compresing roflumilas and (r.r) -formoterol

Publications (1)

Publication Number Publication Date
SI1567140T1 true SI1567140T1 (sl) 2008-12-31

Family

ID=32338001

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331345T SI1567140T1 (sl) 2002-11-27 2003-11-26 Sinergistična kombinacija, ki obsega roflumilastin (R;R)-formoterol

Country Status (31)

Country Link
US (1) US20060199865A1 (enExample)
EP (1) EP1567140B1 (enExample)
JP (1) JP2006508993A (enExample)
KR (1) KR20050094810A (enExample)
CN (1) CN1713902A (enExample)
AT (1) ATE399544T1 (enExample)
AU (1) AU2003288169B8 (enExample)
BR (1) BR0316475A (enExample)
CA (1) CA2506956C (enExample)
CO (1) CO5690571A2 (enExample)
CY (1) CY1110368T1 (enExample)
DE (1) DE60321954D1 (enExample)
DK (1) DK1567140T3 (enExample)
EA (1) EA009990B1 (enExample)
ES (1) ES2309374T3 (enExample)
HR (1) HRP20050580B1 (enExample)
IL (1) IL168307A (enExample)
IS (1) IS2576B (enExample)
MA (1) MA27538A1 (enExample)
ME (1) ME00488B (enExample)
MX (1) MXPA05005438A (enExample)
NO (1) NO334148B1 (enExample)
NZ (1) NZ540658A (enExample)
PL (1) PL214869B1 (enExample)
PT (1) PT1567140E (enExample)
RS (1) RS51082B (enExample)
SI (1) SI1567140T1 (enExample)
TN (1) TNSN05130A1 (enExample)
UA (1) UA83017C2 (enExample)
WO (1) WO2004047828A1 (enExample)
ZA (1) ZA200503307B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
SI1606261T1 (sl) 2003-03-10 2010-03-31 Nycomed Gmbh Novi postopek za pripravo roflumilasta
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
CN103784443A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 一种包含沙美特罗和罗氟司特的药物组合产品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
PT938467E (pt) * 1996-11-11 2002-11-29 Sepracor Inc Processo para a preparacao de isomeros opticamente puros de formoterol
DE69835594T2 (de) * 1997-02-17 2007-08-16 Altana Pharma Ag Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
DK0975347T3 (da) * 1997-02-28 2008-06-16 Nycomed Gmbh Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
TR200100500T2 (tr) * 1998-08-26 2001-06-21 Smithkline Beecham Corporation Pulmoner hastalıkların tedavisi için terapiler
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
CZ302882B6 (cs) * 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (de) * 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
MY137522A (en) * 2001-04-30 2009-02-27 Glaxo Group Ltd Novel anti-inflammatory androstane derivatives.

Also Published As

Publication number Publication date
DK1567140T3 (da) 2008-11-03
HRP20050580A2 (en) 2006-08-31
ME00488B (me) 2011-10-10
BR0316475A (pt) 2005-10-11
ZA200503307B (en) 2006-11-29
RS20050383A (sr) 2007-08-03
TNSN05130A1 (en) 2007-05-14
UA83017C2 (uk) 2008-06-10
CA2506956A1 (en) 2004-06-10
CN1713902A (zh) 2005-12-28
WO2004047828A1 (en) 2004-06-10
EP1567140A1 (en) 2005-08-31
IS2576B (is) 2010-02-15
AU2003288169B8 (en) 2010-08-26
KR20050094810A (ko) 2005-09-28
EA009990B1 (ru) 2008-04-28
RS51082B (sr) 2010-10-31
ATE399544T1 (de) 2008-07-15
CO5690571A2 (es) 2006-10-31
HK1081862A1 (en) 2006-05-26
DE60321954D1 (de) 2008-08-14
IS7899A (is) 2005-06-20
PL375632A1 (en) 2005-12-12
EA200500865A1 (ru) 2005-12-29
CA2506956C (en) 2012-10-02
NO334148B1 (no) 2013-12-16
PL214869B1 (pl) 2013-09-30
AU2003288169A1 (en) 2004-06-18
US20060199865A1 (en) 2006-09-07
NZ540658A (en) 2007-03-30
EP1567140B1 (en) 2008-07-02
NO20053023L (no) 2005-06-20
HRP20050580B1 (hr) 2014-04-11
IL168307A (en) 2010-12-30
PT1567140E (pt) 2008-09-24
CY1110368T1 (el) 2015-04-29
AU2003288169B2 (en) 2010-01-07
ES2309374T3 (es) 2008-12-16
MA27538A1 (fr) 2005-09-01
JP2006508993A (ja) 2006-03-16
MXPA05005438A (es) 2005-08-03

Similar Documents

Publication Publication Date Title
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
HU229439B1 (hu) Roflumilast és salmeterol szinergetikus kombinációja
WO2004043341A3 (en) Treatment for hemorrhagic shock
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
NZ591136A (en) A composition for treating aids and associated conditions comprising plant extracts
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2004103286A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
WO2005046615A3 (en) Compositions for treatment of central nervous system mediated disorders